A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data

Background Smoking is the leading cause of preventable death in the US. While one in five individuals smoke, and 70% of these indicate a desire to quit,

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2011-06, Vol.29 (6), p.497-510
Hauptverfasser:	Xenakis, James G., Kinter, Elizabeth T., Ishak, K. Jack, Ward, Alexandra J., Marton, Jenő P., Willke, Richard J., Davies, Simon, Caro, J. Jaime
Format:	Artikel
Sprache:	eng
Schlagworte:	Abstinence Adult Analysis Benzazepines - therapeutic use Biological and medical sciences Bupropion Cardiovascular disease Clinical trials Clinical Trials as Topic Combinatorics Computerized, statistical medical data processing and models in biomedicine Coronary heart disease Cost-effectiveness Costs Counseling Counselling Drug therapy Female General pharmacology Health Administration Health aspects Health Care Costs Health Economics Humans Intervention Male Medical care, Cost of Medical research Medical sciences Medicine Medicine & Public Health Miscellaneous Models and simulation Models, Statistical Nicotinic Agonists - therapeutic use Original Research Article Patients Pharmaceuticals Pharmacoeconomics and Health Outcomes Pharmacology. Drug treatments Public Health Public health. Hygiene Public health. Hygiene-occupational medicine Quality of Life Research Quinoxalines - therapeutic use Recurrence Risk factors Simulation Smoking Smoking cessation Smoking Cessation - methods Smoking cessation programs Smoking-cessation- therapies Studies therapeutic use Tobacco Use Disorder - drug therapy Tobacco Use Disorder - mortality Tobacco, tobacco smoking Toxicology Treatment Outcome Varenicline
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!